Vardenafil - Benign prostatic hyperplasia
You are here : Home > Formulary Search > Vardenafil - Benign prostatic hyperplasia
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Documentation
PAD Profile
ChemicalSubstance :
Vardenafil
Indication :
Benign prostatic hyperplasia
Group Name :
Keywords :
BPH, LUTS, urinary tract symptoms, urinary frequency, urinary incontinence
Brand Names Include :
Levitra
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1
Other Indications
Below are listed other indications that Vardenafil is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Benign prostatic hyperplasia.
Committee Recommendations (2)
At the Surrey and North-West Sussex Area Prescribing Committee (APC) held in June 2020, it was decided that all BLACK status drugs would have their review dates extended for 5 years without the need for a review.
If a clinician or provider wishes to change the traffic light status of any BLACK drug then they will need to submit a paper for change as per usual APC process.
The PCN does not recommend the use of phosphodiesterase-5 inhibitors for the treatment of lower urinary tract symptoms in men (except as part of a randomised controlled trial) and has assigned a traffic light status to each treatment option as follows.
- Sildenafil - BLACK
- Tadalafil – BLACK
- Avenafil - BLACK
- Vardenafil – BLACK
Patients whose treatment with the above, that were initiated by the NHS before this recommendation was made, must be reviewed by their NHS consultant but should be able to continue treatment until the patient and their NHS consultant consider it appropriate to stop.
- Sildenafil - BLACK
- Tadalafil – BLACK
- Avenafil - BLACK
- Vardenafil – BLACK
Patients whose treatment with the above, that were initiated by the NHS before this recommendation was made, must be reviewed by their NHS consultant but should be able to continue treatment until the patient and their NHS consultant consider it appropriate to stop.